Janssen Loses La. Appeal Of $258M Risperdal Verdict

Law360, New York (August 31, 2012, 4:32 PM EDT) -- A Louisiana appeals court on Friday rejected an attempt by the pharmaceuticals unit of consumer products giant Johnson & Johnson to vacate a jury award of $258 million over its marketing of the antipsychotic drug Risperdal, saying the trial court rightly followed due process.

The three-judge panel rejected Janssen Pharmaceuticals Inc.’s arguments that the lower trial court denied it due process of law by allowing the state attorney general to pursue claims and penalties for alleged regulatory violations with insufficient evidence.

The panel also rejected Janssen’s...
To view the full article, register now.